surpass-cvot tirzepatide Cardiovascular outcomes of semaglutide and for patients with type 2 diabetes in clinical practice Comparison of tirzepatide and dulaglutide
Description
10.2337/diabetes.51.2007.s434 [DOI] [PubMed] 57.Park S, Dong X, Fisher TL, et al
Rather than following the standard escalation to high doses, microdosing involves using smaller amounts more strategically
That said, Tirzepatide tends to cause slightly more nausea, especially at higher dosesnothing too extreme in most cases, but still something to keep in mind
01774-X/asset/3608bfb3-6329-4132-95b7-cc3434437493/main.assets/gr2_lrg.jpg)
Book Your Consultation
And you're comfortable committing to a monthly subscription with the re-rating terms described above if you choose a multi-month plan
